Posted on 7/9/18
3 Top Biotech Stocks to Buy for the 2nd Half of 2018
It seemed almost like a blur, but the first half of 2018 is already history. Generally speaking, biotech stocks didn't perform as well during the first . . .
Posted on 7/9/18
Is Inovio Pharmaceuticals, Inc. a Buy?
Over the last 10 years, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) stock has generated a total return to investors of 2.8%. That performance is definitely underwhelming, to say . . .
Posted on 7/6/18
3 Best Biotech Acquisitions of 2018 (So Far)
If you expected 2018 to be a busy year for biotech mergers and acquisitions activity, you were right. There have already been several huge deals -- . . .
Posted on 7/5/18
Enzyvant Announces Collaboration with Visikol
Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced that it has formed a partnership with Visikol, a contract . . .
Posted on 7/5/18
Phibro Animal Health to Establish New Biotech Facility in Sligo, Ireland, Creating Up To 150 Jobs
TEANECK, N.J., July 05, 2018 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (NASDAQ:PAHC) today announced plans to establish a biotech facility producing a range of innovative . . .
Posted on 7/5/18
Teva: Shopping For Generic Bonds
At some point every investor needs to park money for a year in a safe short-term investment where return of principal is as important as return . . .
Posted on 7/5/18
Teva: Investors Split On Outlook; Near-Term Outlook Not As Bad But Longer-Term Concerns Remain
Fremanezumab Chronic Cluster Trial Failure Seen as Non-Issue, but Cluster Pathway Still UnclearOn June 15, Teva (TEVA) announced that they would be discontinuing their fremanezumab clinical . . .
Posted on 7/3/18
Soligenix Closes $8M At The Market Public Offering
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced . . .
Posted on 7/3/18
CURE Media Group Expands Strategic Alliance Partnership Program with Lung Cancer Alliance
CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, welcomes Lung Cancer Alliance to its . . .
Posted on 7/3/18
Neuronetics Closes IPO
MALVERN, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality . . .
Posted on 7/3/18
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, . . .
Posted on 7/2/18
Cantel Medical Announces Completion of Credit Agreement Refinancing
Cantel Medical Corp. (NYSE: CMD) today announced that it has completed a refinancing of its credit facility by amending the existing agreement to include a $200 . . .
Posted on 7/2/18
University Pediatricians Selects Healthcare Administrative Partners as Outsourced Coding Provider
MEDIA, Pa.--(BUSINESS WIRE)--Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions, today announces the addition of University Pediatricians (UP) to . . .
Posted on 7/2/18
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm's share price . . .
Posted on 7/2/18
Better Buy: Amgen Inc. vs. Pfizer Inc.
Amgen Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) actually have quite a bit in common. They co-market one of the world's best-selling drugs, Enbrel. They both face . . .
Posted on 7/2/18
Celgene Investors Breathe a Sigh of Relief After Acceleron's Success
Celgene Corp. (NASDAQ:CELG) investors would probably like a few do-overs given the company's stumbles over the past year. First, it suffered a key clinical-trial failure that . . .
Posted on 6/28/18
Soligenix Prices $8M Public Offering
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced . . .
Posted on 6/28/18
CURE Magazine Seeks Nominations for 2018 MPN Heroes Recognition Program
CRANBURY, N.J.--(BUSINESS WIRE)--CURE magazine, the nation’s leading digital and print media enterprise focused on patients with cancer, cancer centers and advocacy groups, is accepting nominations for the . . .
Posted on 6/28/18
Johnson & Johnson: A $144 Discounted Cash Flow Valuation
In this article, I will provide a discounted cash flow (NYSE:DCF) valuation for Johnson & Johnson (JNJ). I will first discuss Q1 results because it gives . . .
Posted on 6/27/18
Penn Invests ‘Several Million’ In Carisma Therapeutics As Part Of $50M Biotech Push
The University of Pennsylvania joined a $53 million funding round closed by University City’s Carisma Therapeutics
Posted on 6/27/18
Eight Genesis HealthCare Centers Earn 2018 Bronze National Quality Awards
KENNETT SQUARE, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare, one of the largest post-acute care providers in the United States, today announced that eight . . .
Posted on 6/27/18
Novartis Announces Funding For Patient Advocacy Initiatives
Novartis today announced support for three US-based patient advocacy groups provided through the STEP (Solutions to Empower Patients) Program. The STEP Program is an initiative that . . .
Posted on 6/27/18
Is Pfizer's Lead Growth Driver in Trouble?
Ibrance is a small capsule that's been making a big difference during Pfizer Inc.'s (NYSE:PFE)earnings reports since it launched in 2015. Unfortunately, it didn't make a . . .
Posted on 6/27/18
Saladax Signs Licensing Agreement with Janssen
BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc., a diagnostics company providing kits to measure drug blood levels for adherence and medication management, has signed a license agreement with . . .
Posted on 6/26/18
Will Johnson & Johnson's Pipeline Drugs Offset Sales Erosion To Upcoming Generics?
The Pharmaceutical segment represents ~50% of sales and 66% of operating income, and therefore is key to the bull and bear thesis around Johnson and Johnson . . .

